60376-73-0

Basic information

• Product Name: methyl 3-[[[(dimethylamino)methylene]amino]sulphonyl]-5-nitro-4-phenoxybenzoate
• Synonyms: 3-[[[(Dimethylamino)methylene]amino]sulfonyl]-5-nitro-4-phenoxybenzoic acid methyl ester;Einecs 262-204-8;methyl 3-[[[(dimethylamino)methylene]amino]sulphonyl]-5-nitro-4-phenoxybenzoate
• CAS NO: 60376-73-0
• Molecular Formula: C₁₇H₁₇N₃O₇S
• Molecular Weight: 407.39778
• EINECS: 262-204-8
• Mol File: 60376-73-0.mol

Chemical Properties

• Boiling Point: 544.9°C at 760 mmHg
• Flash Point: 283.3°C
• Appearance: /
• Density: 1.36g/cm³
• Vapor Pressure: 6.25E-12mmHg at 25°C
• Refractive Index: 1.595
• CAS DataBase Reference: methyl 3-[[[(dimethylamino)methylene]amino]sulphonyl]-5-nitro-4-phenoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-[[[(dimethylamino)methylene]amino]sulphonyl]-5-nitro-4-phenoxybenzoate(60376-73-0)
• EPA Substance Registry System: methyl 3-[[[(dimethylamino)methylene]amino]sulphonyl]-5-nitro-4-phenoxybenzoate(60376-73-0)

Safety Data

• Hazardous Substances Data: 60376-73-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C17H17N3O7S/c1-19(2)11-18-28(24,25)15-10-12(17(21)26-3)9-14(20(22)23)16(15)27-13-7-5-4-6-8-13/h4-11H,1-3H3

Upstream product

• 28328-53-2 3-nitro-4-phenoxy-5-sulfamoylbenzoic acid 
• 57939-04-5 3-nitro-4-phenoxy-5-sulfamoylbenzoic acid methyl ester 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 108-95-2 phenol 
• 22892-96-2 4-chloro-3-nitro-5-sulfamoylbenzoic acid 

Downstream Products

• 62243-52-1 3-(cyclopropylmethyl-amino)-5-(dimethylaminomethylene-sulfamoyl)-4-phenoxy-benzoic acid methyl ester 
• 1357465-03-2 3-(bis-cyclopropylmethyl-amino)-5-(dimethylaminomethylene-sulfamoyl)-4-phenoxy-benzoic acid methyl ester 
• 1357458-70-8 3-(bis(cyclopropylmethyl)amino)-4-phenoxy-5-sulfamoylbenzoic acid 
• 1357465-05-4 3-(dimethylaminomethylene-sulfamoyl)-5-dipentylamino-4-phenoxy-benzoic acid methyl ester 
• 1357458-81-1 3-dipentylamino-4-phenoxy-5-sulfamoyl-benzoic acid 
• 1431501-29-9 C₂₂H₂₈N₂O₅S 
• 1431505-42-8 methyl 3-(N-((dimethylamino)methylene)sulfamoyl)-4-phenoxy-5-(piperidin-1-yl)benzoate 
• 57939-09-0 4-phenoxy-3-(piperidin-1-yl)-5-sulfamoylbenzoic acid 
• 28328-53-2 3-nitro-4-phenoxy-5-sulfamoylbenzoic acid 

Relevant articles and documents

2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

Compounds are disclosed that have a formula represented by the following:(I) wherein Cy, L1 R1, R2a, R2b, R3, R4, n, and L2 are as described herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, itch, excessive itch, Pruritis, neuropathic pruritis, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

The present invention provides acylsulfonamides including bumetanide derivatives and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these compounds and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl- co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders (autism), bipolar disorder, cancer, the improvement of cognitive function, cognitive impairment, cognitive dysfunction, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, periodic limb movement disorder (PLMD), personality disorders, postherpetic neuralgia, psychosis, restless legs syndrome (RLS), schizophrenia, seizure disorders, spasticity, tinnitus, and withdrawal syndromes.

5-Sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent

5-Sulfamoylbenzoic acids substituted in 4-position by various substituents and in 3-position by a cyclic amino group having sali-diurectic properties, and a process for their manufacture.